All In Biotech

Drug Trial Radar · NCT00091832

Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

A Randomized Active-controlled Study of AMG 162 in Breast Cancer Subjects With Bone Metastasis Who Have Not Previously Been Treated With Bisphosphonate Therapy.

Last checked: Nov 20, 2026Latest source record: Jan 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

255

Actual

Start

Sep 2004

Primary completion

Nov 2005

Study completion Oct 2006

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Sep 21, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate various doses and schedules for denosumab administration and characterize the safety profile in this indication.

Conditions

  • Breast Cancer
  • Metastases
  • Bone Metastases in Subjects With Advanced Breast Cancer

Interventions

  • DenosumabBiological

    Denosumab administered by subcutaneous injection

  • IV BisphosphonatesDrug

    Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr)Time frame: Baseline and Week 13

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.